TD Cowen analyst Steven Mah reiterated a Buy rating on Cytek Biosciences (CTKB – Research Report) today. The company’s shares opened today at $8.00.
According to TipRanks, Mah is an analyst with an average return of -10.0% and a 30.65% success rate. Mah covers the Healthcare sector, focusing on stocks such as BioLife Solutions, Twist Bioscience, and Cytek Biosciences.
Cytek Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $9.25.
See Insiders’ Hot Stocks on TipRanks >>
CTKB market cap is currently $1.09B and has a P/E ratio of -77.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytek Biosciences (CTKB) Company Description:
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
Read More on CTKB:
